BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29202805)

  • 1. Clinical significance of PCDH10 promoter methylation in diffuse large B-cell lymphoma.
    Huang W; Xue X; Shan L; Qiu T; Guo L; Ying J; Lu N
    BMC Cancer; 2017 Dec; 17(1):815. PubMed ID: 29202805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High methylation levels of PCDH10 predict poor prognosis in patients with pancreatic ductal adenocarcinoma.
    Curia MC; Fantini F; Lattanzio R; Tavano F; Di Mola F; Piantelli M; Battista P; Di Sebastiano P; Cama A
    BMC Cancer; 2019 May; 19(1):452. PubMed ID: 31088413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of the methylated cytosine-phosphate-guanine sites of protocadherin-10 promoter for evaluating the prognosis of gastric cancer.
    Deng J; Liang H; Ying G; Dong Q; Zhang L; Yu J; Fan D; Hao X
    J Am Coll Surg; 2014 Nov; 219(5):904-13. PubMed ID: 25260683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCDH10 promoter hypermethylation is frequent in most histologic subtypes of mature lymphoid malignancies and occurs early in lymphomagenesis.
    Narayan G; Xie D; Freddy AJ; Ishdorj G; Do C; Satwani P; Liyanage H; Clark L; Kisselev S; Nandula SV; Scotto L; Alobeid B; Savage D; Tycko B; O'Connor OA; Bhagat G; Murty VV
    Genes Chromosomes Cancer; 2013 Nov; 52(11):1030-41. PubMed ID: 23929756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma.
    Hiraga J; Kinoshita T; Ohno T; Mori N; Ohashi H; Fukami S; Noda A; Ichikawa A; Naoe T
    Int J Hematol; 2006 Oct; 84(3):248-55. PubMed ID: 17050200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic impact of hypermethylation for a panel of tumor suppressor genes and cell of origin subtype on diffuse large B-cell lymphoma.
    Shawky SA; El-Borai MH; Khaled HM; Guda I; Mohanad M; Abdellateif MS; Zekri AN; Bahanasy AA
    Mol Biol Rep; 2019 Aug; 46(4):4063-4076. PubMed ID: 31093876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma.
    Voropaeva EN; Pospelova TI; Voevoda MI; Maksimov VN; Orlov YL; Seregina OB
    BMC Med Genomics; 2019 Mar; 12(Suppl 2):35. PubMed ID: 30871527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the clinical feasibility: The direct bisulfite genomic sequencing for examination of methylated status of protocadherin10 (PCDH10) promoter to predict the prognosis of gastric cancer.
    Hou YC; Deng JY; Zhang RP; Xie XM; Cui JL; Wu WP; Hao XS; Liang H
    Cancer Biomark; 2015; 15(5):567-73. PubMed ID: 26406945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer.
    Harada H; Miyamoto K; Yamashita Y; Taniyama K; Mihara K; Nishimura M; Okada M
    Cancer Med; 2015 Oct; 4(10):1536-46. PubMed ID: 26276761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma.
    Nakamichi I; Tomita Y; Zhang B; Sugiyama H; Kanakura Y; Fukuhara S; Hino M; Kanamaru A; Ogawa H; Aozasa K
    Ann Hematol; 2007 Aug; 86(8):557-64. PubMed ID: 17508213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma.
    Kristensen LS; Hansen JW; Kristensen SS; Tholstrup D; Harsløf LB; Pedersen OB; De Nully Brown P; Grønbæk K
    Clin Epigenetics; 2016; 8(1):95. PubMed ID: 27610206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter methylation-mediated inactivation of PCDH10 in acute lymphoblastic leukemia contributes to chemotherapy resistance.
    Narayan G; Freddy AJ; Xie D; Liyanage H; Clark L; Kisselev S; Un Kang J; Nandula SV; McGuinn C; Subramaniyam S; Alobeid B; Satwani P; Savage D; Bhagat G; Murty VV
    Genes Chromosomes Cancer; 2011 Dec; 50(12):1043-53. PubMed ID: 21960365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global hypomethylation is an independent prognostic factor in diffuse large B cell lymphoma.
    Wedge E; Hansen JW; Garde C; Asmar F; Tholstrup D; Kristensen SS; Munch-Petersen HD; Ralfkiaer E; Brown P; Grønbaek K; Kristensen LS
    Am J Hematol; 2017 Jul; 92(7):689-694. PubMed ID: 28378885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of O6-methylguanine-DNA methyltransferase protein expression is a favorable prognostic marker in diffuse large B-cell lymphoma.
    Ohno T; Hiraga J; Ohashi H; Sugisaki C; Li E; Asano H; Ito T; Nagai H; Yamashita Y; Mori N; Kinoshita T; Naoe T
    Int J Hematol; 2006 May; 83(4):341-7. PubMed ID: 16757436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative evaluation of p16(INK4a) promoter methylation using pyrosequencing in de novo diffuse large B-cell lymphoma.
    Zainuddin N; Kanduri M; Berglund M; Lindell M; Amini RM; Roos G; Sundström C; Enblad G; Rosenquist R
    Leuk Res; 2011 Apr; 35(4):438-43. PubMed ID: 21035853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer.
    Yu J; Cheng YY; Tao Q; Cheung KF; Lam CN; Geng H; Tian LW; Wong YP; Tong JH; Ying JM; Jin H; To KF; Chan FK; Sung JJ
    Gastroenterology; 2009 Feb; 136(2):640-51.e1. PubMed ID: 19084528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies.
    Ying J; Gao Z; Li H; Srivastava G; Murray PG; Goh HK; Lim CY; Wang Y; Marafioti T; Mason DY; Ambinder RF; Chan AT; Tao Q
    Br J Haematol; 2007 Mar; 136(6):829-32. PubMed ID: 17341268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic changes and their clinical relevance in Saudi diffuse large B-cell lymphoma. A molecular and tissue microarray analysis of 100 cases.
    Al-Kuraya KS; Siraj AK; Al-Dayel FA; Ezzat AA; Al-Jommah NA; Atizado VL; Narayanappa RN
    Saudi Med J; 2005 Jul; 26(7):1099-103. PubMed ID: 16047061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1.
    Heitzer E; Artl M; Filipits M; Resel M; Graf R; Weißenbacher B; Lax S; Gnant M; Wrba F; Greil R; Dietze O; Hofbauer F; Böhm G; Höfler G; Samonigg H; Schaberl-Moser R; Balic M; Dandachi N
    Mod Pathol; 2014 Jun; 27(6):906-15. PubMed ID: 24309322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Value of Protocadherin10 (PCDH10) Methylation in Serum of Prostate Cancer Patients.
    Deng QK; Lei YG; Lin YL; Ma JG; Li WP
    Med Sci Monit; 2016 Feb; 22():516-21. PubMed ID: 26881880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.